BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology comp

Vor Biopharma (VOR) has transformed into a late-stage autoimmune drug developer, focusing on telitac

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology comp

Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery for

First regulatory approval for Sjögren's disease (SjD) First and only approved therapy for SjD in Chi

First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN)  Approval based on p

BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnolo

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology compa

Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks w

Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis p

The consensus price target hints at a 124.6% upside potential for Vor Biopharma (VOR). While empiric

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology compa

The average of price targets set by Wall Street analysts indicates a potential upside of 117% in Vor

Top Wall Street analysts changed their outlook on these top names. See analyst rating changes and up

Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) was the target of a large growth in short interes

Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) Director Ra Capital Management, L.P. sold 484,104

Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) Director Ra Capital Management, L.P. sold 135,201

Vor Biopharma Inc. has pivoted to immunology, raising over $500m in 2025 to advance telitacicept for

Shares of Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) have earned a consensus rating of "Mode

Vor Biopharma (VOR) might move higher on growing optimism about its earnings prospects, which is ref

The average of price targets set by Wall Street analysts indicates a potential upside of 107.8% in V

U.S. stocks lower, Nasdaq falls 1%. Oxford Industries up 11.2% on strong earnings, raised dividend.

  On Tuesday, 647 companies set new 52-week lows.

  During the session on Thursday, 461 stocks hit new 52-week lows.

  On Tuesday, 838 companies hit new 52-week lows.

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 51% to $0.4957. Crown ElectroKin

  On Wednesday, 807 companies reached new 52-week lows.

    On Monday, 147 stocks hit new 52-week lows.